Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
8 hedge funds and large institutions have $251K invested in Biostar Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
64% less capital invested
Capital invested by funds: $697K → $251K (-$446K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$76.6K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$62.6K |
| 3 |
Morgan Stanley
New York
|
+$16.9K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$468K |
| 2 |
Jane Street
New York
|
-$69K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$66K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
1
Acrospire Investment Management
Chicago,
Illinois
| $86K | +$76.6K | +20,999 | +1,050% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $64K | +$62.6K | +17,163 | New |
|
|
CS
3
Credit Suisse
Zurich,
Switzerland
| $41K | -$66K | -18,093 | -62% |
|
|
4
UBS Group
Zurich,
Switzerland
| $24K | +$6.21K | +1,703 | +36% |
|
|
5
Morgan Stanley
New York
| $17K | +$16.9K | +4,627 | +19,279% |
|
|
6
Acadian Asset Management
Boston,
Massachusetts
| $16K | +$15.3K | +4,197 | New |
|
7
Barclays
London,
United Kingdom
| $3K | +$2.98K | +817 | New |
|
|
8
Renaissance Technologies
New York
| – | -$468K | -105,956 | Closed |
|
|
9
Jane Street
New York
| – | -$69K | -15,556 | Closed |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$1K | -143 | Closed |
|
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$4 | -1 | -50% |
|
BSPM Hedge Fund Activity: Q3 2016 in Review
8 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q3 2016, worth a combined $251K — down 64% from $697K a quarter earlier.
Fund positioning in BSPM was balanced in Q3 2016: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Acrospire Investment Management, adding an estimated $76.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $468K sold.
- 8 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $251K of Biostar Pharmaceuticals, Inc. stock for Q3 2016, down 64% quarter-over-quarter.
- 3 funds opened new Biostar Pharmaceuticals, Inc. positions in Q3 2016 and 3 closed out, a net change of 0 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q3 2016 was Acrospire Investment Management, an estimated $76.6K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q3 2016 was Renaissance Technologies, an estimated $468K sold.
Based on aggregated 13F filings for Q3 2016.